Differences in outcomes and quality of life across commonly used treatments for endocrine-refractory and triple-negative metastatic breast cancer were "razor-thin," leaving cost as a key factor.
Medscape Medical News
Cost Paramount When Choosing Metastatic Breast Cancer Treatment
